Starboard Agreement Tilts Perrigo Toward Rx Generics Sale
This article was originally published in The Pink Sheet
OTC private label giant agrees with Starboard, which owns around 6.7% of Perrigo's shares, to immediately add to Perrigo's board Starboard CEO Jeffrey Smith and two other members recommended by the hedge fund: former Pfizer CEO Jeffrey Kindler and Nestle USA executive Bradley Alford.
You may also be interested in...
Perrigo reports 4% Q2 sales growth for OTC drugs in the Americas region was offset by nearly 15% drop in infant formula sale. Total consumer sales in the Americas slipped 2.5% to $582m, but CEO Murray Kessler says brighter days are ahead on benefits from Ranir oral care acquisition.
Perrigo reorganizes its reporting segments to better align with its organizational structure; consumer product units are combined and renamed.
A portfolio review concluded that 'the next step to unlock shareholder value is … exploring strategic alternatives for that Tysabri royalty stream,' CEO John Hendrickson said during Perrigo's third-quarter earnings briefing.